PL432011A1 - MiRNA biomarkers for the differential diagnosis of histopathological sub-types of non small cell lung cancer - Google Patents

MiRNA biomarkers for the differential diagnosis of histopathological sub-types of non small cell lung cancer

Info

Publication number
PL432011A1
PL432011A1 PL432011A PL43201119A PL432011A1 PL 432011 A1 PL432011 A1 PL 432011A1 PL 432011 A PL432011 A PL 432011A PL 43201119 A PL43201119 A PL 43201119A PL 432011 A1 PL432011 A1 PL 432011A1
Authority
PL
Poland
Prior art keywords
mirna
panel
mirna biomarkers
biomarkers
differential
Prior art date
Application number
PL432011A
Other languages
Polish (pl)
Other versions
PL241607B1 (en
Inventor
Radosław CHARKIEWICZ
Attila GYENESEI
Bence GÁLIK
Jacek NIKLIŃSKI
Joanna RESZEĆ
Mirosław KOZŁOWSKI
Anetta SULEWSKA
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL432011A priority Critical patent/PL241607B1/en
Priority to PCT/PL2019/000113 priority patent/WO2021107791A1/en
Publication of PL432011A1 publication Critical patent/PL432011A1/en
Publication of PL241607B1 publication Critical patent/PL241607B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem niniejszego wynalazku jest sposób różnicowego diagnozowania in vitro raka gruczołowego płuca (AC) względem raka płaskonabłonkowego płuca (SCC) u osobnika, w którym to sposobie oznacza się ilościowo poziom ekspresji dla panelu wyselekcjonowanych biomarkerów miRNA i identyfikuje się sygnaturę miRNA. Przedmiotem niniejszego wynalazku jest ponadto sposób różnicowego diagnozowania in vitro raka płaskonabłonkowego płuca (SCC) względem raka gruczołowego płuca (AC) u osobnika, w którym to sposobie oznacza się ilościowo poziom ekspresji dla panelu wyselekcjonowanych biomarkerów miRNA i identyfikuje się sygnaturę miRNA. Przedmiotem wynalazku jest również panel wyselekcjonowanych biomarkerów miRNA oraz zastosowania takiego panelu biomarkerów miRNA w diagnostyce. Przedmiotem wynalazku jest ponadto zestaw do różnicowego diagnozowania in vitro raka gruczołowego płuca względem raka płaskonabłonkowego płuca zawierający środki do ilościowego oznaczania poziomu ekspresji panelu biomarkerów miRNA oraz zestaw do różnicowego diagnozowania in vitro raka płaskonabłonkowego płuca względem raka gruczołowego płuca zawierający środki do ilościowego oznaczania poziomu ekspresji panelu biomarkerów miRNA.The present invention relates to a method for differential in vitro diagnosis of lung adenocarcinoma (AC) versus squamous cell carcinoma (SCC) in a subject, wherein the method quantifies the expression level of a panel of selected miRNA biomarkers and identifies the miRNA signature. The present invention further relates to a method for differential in vitro diagnosis of squamous cell carcinoma of the lung (SCC) versus lung adenocarcinoma (AC) in a subject, wherein the method quantifies the expression level of a panel of selected miRNA biomarkers and identifies the miRNA signature. The subject of the invention is also a panel of selected miRNA biomarkers and the use of such a panel of miRNA biomarkers in diagnostics. The invention further relates to a kit for the differential in vitro diagnosis of lung adenocarcinoma against squamous cell carcinoma of the lung comprising means for quantifying the expression level of a panel of miRNA biomarkers and a kit for the differential diagnosis in vitro of lung squamous cell carcinoma against lung adenocarcinoma containing means for quantifying the level of expression of a panel of biomarkers miRNA.

PL432011A 2019-11-29 2019-11-29 Panel of miRNA biomarkers for differential diagnosis of histopathological subtypes of non-small cell lung cancer PL241607B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL432011A PL241607B1 (en) 2019-11-29 2019-11-29 Panel of miRNA biomarkers for differential diagnosis of histopathological subtypes of non-small cell lung cancer
PCT/PL2019/000113 WO2021107791A1 (en) 2019-11-29 2019-11-30 Mirna biomarkers for differential diagnosis of histopathological subtypes of non-small cell lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432011A PL241607B1 (en) 2019-11-29 2019-11-29 Panel of miRNA biomarkers for differential diagnosis of histopathological subtypes of non-small cell lung cancer

Publications (2)

Publication Number Publication Date
PL432011A1 true PL432011A1 (en) 2021-05-31
PL241607B1 PL241607B1 (en) 2022-11-07

Family

ID=69374347

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432011A PL241607B1 (en) 2019-11-29 2019-11-29 Panel of miRNA biomarkers for differential diagnosis of histopathological subtypes of non-small cell lung cancer

Country Status (2)

Country Link
PL (1) PL241607B1 (en)
WO (1) WO2021107791A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116334230A (en) * 2023-05-08 2023-06-27 天津市肿瘤医院（天津医科大学肿瘤医院） A lung adenocarcinoma marker and its application in the preparation of a lung adenocarcinoma screening kit or treatment monitoring kit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076145A1 (en) * 2009-12-24 2011-06-30 Fudan University Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer
CN103764844A (en) * 2011-03-28 2014-04-30 罗塞塔金诺米克斯有限公司 Methods for lung cancer clasification

Also Published As

Publication number Publication date
PL241607B1 (en) 2022-11-07
WO2021107791A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
Litvak et al. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging
Kutlu et al. Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients
EP4464797A3 (en) Kit, device, and method for detecting lung cancer
EP4458849A3 (en) Biomarkers for pancreatic cancer
NZ597363A (en) Prognosis prediction for colorectal cancer
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
WO2022174234A3 (en) Biomarkers for cancer treatment
BR112016013976A2 (en) Method to determine if an individual is affected by a cancer, Method to discriminate between colorectal and pancreatic cancer among individuals who turn out to be positive for the method, Method to determine the stage of a colorectal cancer in an affected individual, and Use of an rt kit -pcr quantitative to perform the method
MX2019000091A (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer.
Ferro et al. High-grade T1 on re-transurethral resection after initial high-grade T1 confers worse oncological outcomes: results of a multi-institutional study
GB2543239A (en) An online meeting system and method
MX2020014091A (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor.
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
Zhang et al. Diminished miR-613 expression as a novel prognostic biomarker for human ovarian cancer
CL2020003204A1 (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with treatment
PL432011A1 (en) MiRNA biomarkers for the differential diagnosis of histopathological sub-types of non small cell lung cancer
WO2016005905A3 (en) Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages
GB201222576D0 (en) Method for diagnosing lung cancer
ES2672989T3 (en) FALZ for use as a target for therapies to treat cancer
EP3557259A3 (en) Methods and arrays for use in the same
Ge et al. Positive MACC1 expression correlates with invasive behaviors and postoperative liver metastasis in colon cancer
GB2552271A (en) A method for diagnosing lung cancer
Harris et al. Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck
MY206091A (en) Methods based on the detection of rad51 foci in tumor cells